ATB Therapeutics
Latest round
- Series A
Last raised
- Oct 2024
Total raised
- $16M
Investors
- 7
About ATB Therapeutics
Based in Belgium and founded by co-founders Bertrand Magy (CEO), Ludwig Camusot, and Max Houry, ATB Therapeutics, Inc. specializes in creating targeted therapies for oncology and autoimmune diseases. In November 2024, ATB Therapeutics, Inc. ATB Therapeutics specializes in developing therapeutic solutions intended to address critical needs in oncology and autoimmune diseases. Their core offerings include the atbody, a biologic format intended for targeted antibody therapies, particularly effective in treating hematological malignancies and autoimmune conditions. Additionally, the company offers Atbiofarm, a plant-based manufacturing technology that improves the production capabilities of their therapeutic products. These solutions target healthcare providers and institutions focused on oncology and immunology, with plans to expand their pipeline in solid tumors to meet unmet clinical needs across markets in Europe and North America. ATB Therapeutics's revenue generation is primarily driven by partnerships and collaborations with healthcare organizations and pharmaceutical companies. Through strategic alliances, the company engages in business transactions involving the development and commercialization of its flagship products, including the ATB Ody and the ATB IOFarm technology. The company plans to enhance its product offerings, focusing on new therapies aimed at solid tumors.
Who invested in ATB Therapeutics
7 investors across 1 round
See all investors in ATB Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 29, 2024
Amount
$16M
Investors
Questions about ATB Therapeutics
Who invested in ATB Therapeutics?
ATB Therapeutics has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ATB Therapeutics raised?
ATB Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ATB Therapeutics last raise money?
ATB Therapeutics's most recent round on record is a Series A, in Oct 2024.
What does ATB Therapeutics do?
Based in Belgium and founded by co-founders Bertrand Magy (CEO), Ludwig Camusot, and Max Houry, ATB Therapeutics, Inc.
Where is ATB Therapeutics headquartered?
ATB Therapeutics is headquartered in Belgium.
Which VCs invest in companies like ATB Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at ATB Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ATB Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.